Login / Signup

A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors.

Michele VigoloMelissa G ChambersLaure WillenDehlia ChevalleyKlaus MaskosAlfred LammensAubry TardivelDolon DasChristine Kowalczyk-QuintasSonia Schuepbach-MallepellCristian R SmulskiMahya EslamiAntonius RolinkEdith HummlerEileen SamyYves Fomekong NanfackFabienne MackayMaofu LiaoHenry HessXuliang JiangPascal Schneider
Published in: Nature communications (2018)
The B cell survival factor (TNFSF13B/BAFF) is often elevated in autoimmune diseases and is targeted in the clinic for the treatment of systemic lupus erythematosus. BAFF contains a loop region designated the flap, which is dispensable for receptor binding. Here we show that the flap of BAFF has two functions. In addition to facilitating the formation of a highly active BAFF 60-mer as shown previously, it also converts binding of BAFF to TNFRSF13C (BAFFR) into a signaling event via oligomerization of individual BAFF-BAFFR complexes. Binding and activation of BAFFR can therefore be targeted independently to inhibit or activate the function of BAFF. Moreover, structural analyses suggest that the flap of BAFF 60-mer temporarily prevents binding of an anti-BAFF antibody (belimumab) but not of a decoy receptor (atacicept). The observed differences in profiles of BAFF inhibition may confer distinct biological and clinical efficacies to these therapeutically relevant inhibitors.
Keyphrases
  • systemic lupus erythematosus
  • primary care
  • transcription factor
  • rheumatoid arthritis
  • mouse model
  • dna binding
  • drug delivery
  • breast reconstruction
  • replacement therapy